Ajanta Pharma Ltd. share price target

Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~12% CAGR in...

Ajanta reported growth across most of the financial line items YoY and QoQ. Revenue/EBITDA/PAT grew by 20%/7%/9%YoY, while sequentially it grew by 19%/32%/30%. However, gross and EBITDA margins declined 700bps and 335bps YoY....

Domestic formulations - Focus on new launches, few therapies Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~12% CAGR in...

Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in the dermatology segment due to increased competition in existing products and slow offtake in new launches may impact near term...

1 May 2019 Revenue declined 3% YoY to INR5.1b (in-line) in 4QFY19, largely on account of the weakness in (a) institutional anti-malaria (-26% YoY; 9% of sales) and (b) Africa branded generic (-31% YoY; 15% of sales) businesses. However, the impact was partly mitigated by the ramp-up in US sales (+79% YoY; 15% of sales) and steady growth in the India business (+8% YoY; 30% of sales)/Asia (+9% YoY; 28% of sales). EBITDA margin, too, contracted 164bp YoY to 24.7% (our v/s 19.8% in the year-ago period) and RM cost. Other expenses, however, declined to 34% of sales (36.2% in 4QFY18), providing some comfort to the FY19, sales/EBITDA/PAT declined 4%/14%/17% YoY to INR20.5b/INR5.6b/INR3.8b. In FY19, AJP filed 13 and received 12 ANDA approvals (including two tentative approvals). The company has commercialized 25 ANDAs till date.

Ajanta Pharma's Q3FY19 results were below I-direct estimates on all fronts mainly due to lower-than-exacted export formulation sales Revenues declined 17.4% YoY to | 485.1 crore (I-direct estimate: | 522.6 crore) due to 26.7% YoY decline in export formulations to...

Ajanta Pharma Ltd Q2FY19 results Comment Revenue increased by 6.48% to Rs. 544.11 Cr in Q2FY19 when compared to the previous quarter. Also, it rose by 0.69% when compared with Q2FY18

Ajanta Pharma (AJP) has delivered a better-than-expected performance on all operational metrics in 2QFY19 led by strong sales growth in Asia/US as well as lower-than-expected decline in Africa sales. Domestic business reported flat growth due to high YoY base led by channel re-filling post GST roll-out. Despite marginal sales growth, AJP's EBITDA de-grew by 9.5% YoY to Rs1.7bn on account of higher staff and other operating expenditure, owing to which EBITDA margin contracted by 345bps YoY to 30.5%. However, AJP's gross margin expanded by 255bps YoY to 82.4% due to better product-mix. Led by higher taxes, PAT de-grew by 4.9% YoY to Rs1.3bn. The Company is expected to file 10-12 ANDAs with the USFDA in FY19E. LPC maintained...

ICICI Securities Ltd | Retail Equity Research Ajanta Pharma's Q2FY19 results were above I-direct estimates on all fronts mainly on account of a beat in export sales and higher other income. Revenues grew 0.7% YoY to | 544.1 crore. Muted growth was mainly due to the high base of restocking in domestic market post GST implementation and shrinking in African tender business. Beat vis--vis I-direct estimates was due to strong US sales EBITDA margins contracted 345 bps YoY to 30.5% (I-direct...

ICICI Securities Ltd | Retail Equity Research Revenues grew 8% YoY to | 511.0 crore (I-direct estimate: | 473.6 crore) mainly due to 24.5% YoY growth in domestic formulations to | 178.0 crore (I-direct estimate: | 175.0 crore) and 34.4% growth in Asia business to | 129 crore (I-direct estimate: | 134 crore) EBITDA margins improved 320 bps YoY to 30.8% (I-direct estimate: 25.8%) mainly due to strong gross margins and lower other expenditure. EBITDA grew 20.5% YoY to | 157.5 crore...